Whether it is denial or a blatant attempt to decieve, as the European Union revisits its tobacco tax framework, officials in Brussels are increasingly framing public opposition not as democratic feedback, but as suspect behaviour. Faced with a wave of criticism over proposed excise reforms, the European Commission has suggested that much of the resistance may be the result of coordinated industry interference rather than genuine concern from citizens, consumers, and experts.
That framing may be politically convenient. It is also deeply revealing. According to Commission representatives, a surge of late-stage submissions to public consultations supporting harm reduction–aligned positions appeared “artificial” or “organised.” Officials have pointed to allegedly fabricated responses attributed to public health professionals and warned of lobbying activity reminiscent of previous tobacco consultations, including one in the United Kingdom where automated submissions were identified.
Is it denial or an attack on democracy?
What is striking, however, is not that lobbying exists — it always has — but how readily EU institutions appear willing to dismiss widespread public opposition to higher taxes on safer nicotine products as illegitimate. Rather than grappling with the substance of the criticism, the Commission is signalling that if too many people disagree, the explanation must be manipulation.
In doing so, Brussels avoids a far more uncomfortable possibility: that its tax proposals are genuinely unpopular because they conflict with evidence, experience, and basic harm reduction principles.
The controversy comes as the EU prepares sweeping changes to tobacco and nicotine regulation. Central to this is a revision of the Tobacco Excise Directive, which would substantially raise minimum cigarette taxes across the bloc. While framed as a public health measure, the proposal has already triggered resistance from multiple member states concerned about affordability, illicit trade, and unintended consequences. In response, compromise options featuring slightly lower rates and delayed implementation are now being discussed.
Pushing forward at all costs?
Running parallel to this effort is a broader regulatory push targeting emerging nicotine products such as e-cigarettes, heated tobacco, and nicotine pouches. These products are expected to face tighter marketing rules, flavour restrictions, and new tax regimes, despite overwhelming scientific consensus that they expose users to far fewer harmful substances than combustible cigarettes.
Price-driven substitution away from cigarettes is one of the most powerful tools public health has. When safer alternatives are clearly cheaper and more accessible, smoking rates fall.
It is here that the Commission’s stance becomes increasingly difficult to defend. Harm reduction advocates, medical experts, and economists have repeatedly pointed out that nicotine products are not interchangeable in terms of risk. Combustion not nicotine, is responsible for the vast majority of smoking-related disease and death. This distinction is not controversial in the scientific literature. It is acknowledged by leading health agencies, reflected in Cochrane systematic reviews, and supported by regulators and medical entities across multiple countries.
Yet EU tax policy continues to move in the opposite direction, seeking to narrow price differences between cigarettes and far safer alternatives. The draft revision circulated by the Cypriot presidency makes this explicit. Although some excise levels are lower than those originally proposed by the Commission, the document states a clear intention to prevent “tax-driven substitution” between nicotine products.
From a harm reduction perspective, that goal is not a safeguard, it is the problem. Price-driven substitution away from cigarettes is one of the most powerful tools public health has. When safer alternatives are clearly cheaper and more accessible, smoking rates fall. When that incentive is removed, smokers do not quit nicotine; they keep smoking. This is not theory. It is observable in real-world data.
Canada offers one of the most recent and clearest examples of this. Provinces that imposed strict regulations and taxes on vaping products, often justified as precautionary measures, saw cigarette sales rise by nearly 10 percent on average. This occurred despite Canada already having some of the world’s toughest tobacco controls, including plain packaging and menthol cigarette bans. Similar substitution effects have been documented across multiple U.S. states following flavour bans and tax hikes on vaping products.
The EU’s own member states provide further evidence. Sweden, which has embraced harm reduction through access to low-risk oral nicotine products, has achieved Europe’s lowest smoking rates and significantly lower smoking-related cancer mortality. Crucially, this success coincided with a tax framework that did not punish safer alternatives. Real-world data from Sweden also directly contradict claims that smoke-free products act as gateways to smoking.
Ignorant or simply deceitful?
Against this backdrop, it is hardly surprising that public opposition to the Commission’s tax plans has been intense. Consumers, clinicians, and researchers are responding to proposals that would make quitting harder, particularly for lower-income smokers who are most sensitive to price signals. Dismissing that opposition as industry interference allows policymakers to avoid engaging with these realities.
In fact, member states with strong harm reduction records, including Sweden, Greece, and the Czech Republic, have reportedly resisted both the original Commission proposal and the revised compromise. They are seeking to preserve national strategies that have delivered measurable reductions in smoking, rather than sacrifice them to ideological uniformity. What the Commission characterises as “suspicious” opposition is more likely the predictable response of people who understand the stakes.
Europe faces a choice. It can continue to conflate all nicotine products, dismiss criticism as interference, and double down on policies that protect cigarette dominance. Or it can accept that widespread opposition reflects a growing consensus: taxation should be proportional to risk, substitution away from smoking should be encouraged, and harm reduction works. Calling dissent manipulation does not make the evidence disappear. It merely delays the reckoning and prolongs the toll of smoking-related disease that EU policy claims to oppose.
